Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 409

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Open access
Smolen, Josef S, Landewé, Robert, Breedveld, Ferdinand C, Dougados, Maxime, Emery, Paul, Gaujoux-Viala, Cecile, Gorter, Simone, Knevel, Rachel, Nam, Jackie, Schoels, Monika, Aletaha, Daniel, Buch, Maya, Gossec, Laure, Huizinga, Tom, Bijlsma, Johannes W J W, Burmester, Gerd, Combe, Bernard, Cutolo, Maurizio, Gabay, Cem, Gomez-Reino, Juan, Kouloumas, Marios, Kvien, Tore K, Martin-Mola, Emilio, McInnes, Iain, Pavelka, Karel, van Riel, Piet, Scholte, Marieke, Scott, David L, Sokka, Tuulikki, Valesini, Guido, van Vollenhoven, Ronald, Winthrop, Kevin L, Wong, John, Zink, Angela, van der Heijde, Désirée·2010·Annals of the Rheumatic Diseases

Abstract

Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear and consensual international recommendations on RA treatment are not available. In this paper recommendations for the treatment of RA with synthetic and biological disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs) that also account for strategic algorithms and deal with economic aspects, are described. The recommendations are based on evidence from five systematic literature reviews (SLRs) performed for synthetic DMARDs, biological DMARDs, GCs, treatment strategies and economic issues. The SLR-derived evidence was discussed and summarised as an expert opinion in the course of a Delphi-like process. Levels of evidence, strength of recommendations and levels of agreement were derived. Fifteen recommendations were developed covering an area from general aspects such as remission/low disease activity as treatment aim via the preference for methotrexate monotherapy with or without GCs vis-à-vis combination of synthetic DMARDs to the use of biological agents mainly in patients for whom synthetic DMARDs and tumour necrosis factor inhibitors had failed. Cost effectiveness of the treatments was additionally examined. These recommendations are intended to inform rheumatologists, patients and other stakeholders about a European consensus on the management of RA with DMARDs and GCs as well as strategies to reach optimal outcomes of RA, based on evidence and expert opinion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/ard.2009.126532

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Smolen, J. S., Landewé, R., Breedveld, F. C., Dougados, M., Emery, P., Gaujoux-Viala, C., Gorter, S., Knevel, R., Nam, J., Schoels, M., Aletaha, D., Buch, M., Gossec, L., Huizinga, T., Bijlsma, J. W. J. W., Burmester, G., Combe, B., Cutolo, M., Gabay, C., Gomez-Reino, J., Kouloumas, M., Kvien, T. K., Martin-Mola, E., McInnes, I., Pavelka, K., van Riel, P., Scholte, M., Scott, D. L., Sokka, T., Valesini, G., van Vollenhoven, R., Winthrop, K. L., Wong, J., Zink, A., & van der Heijde, D.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2010-06
Volume
69
Issue
6
Pages
964-975
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2607079988
Cited by
409
References
3
FWCI
46.17
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.